Mike Davies presents at the “Adaptive Designs in Clinical Trials” conference

Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4^th April 2017.

In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead compound, BB2603, a novel nanoparticle formulation of terbinafine, to treat onychomycosis and tinea pedis.